Related Experiment Video
Updated: May 9, 2026

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
Published on: October 16, 2018
Persistence of HIV-1 transmitted drug resistance mutations
Hannah Castro1, Deenan Pillay, Patricia Cane
1Medical Research Council Clinical Trials Unit, London, United Kingdom.
None:
There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.
Related Concept Videos
Retrovirus Life Cycles
Treatment Resistant Cancers
Viral Mutations
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Desensitization and Tachyphylaxis
Several...

